



Mycobiome sequencing – can we use it for diagnosing fungal infection?


Danielle Weaver

Manchester Fungal Infection Group




Diagnosing fungal infections

- Direct microscopy and culture methods
 - time consuming
 - require technical expertise
- GM and β -D-Glucan testing
 - fail to detect some fungal pathogens
 - don't identify the organism causing the positive result
- New diagnostics with broad species coverage & good speciation are warranted




Mycobiome sequencing

- Mycobiome – the fungal community in and on an organism
- A few targets have been reported in the literature – all are ribosomal RNA regions
- The Internal transcribed spacer (ITS) regions have become standard, particularly ITS1





Fungal ribosomal RNA



Mycobiome varies in health & disease – Can we harness it for diagnostics?


- High throughput sample processing
- Sensitive = good limit of detection
- Specificity – depends on chosen primers
- Potential to provide a complete picture of all species within a sample in a quantitative manner



Pitfalls of ITS for use in an NGS fungal diagnostic

- Amplicon not consistent in length – PCR bias against some species
- Variable copy number in fungal genomes (13-fold between *A. fumigatus* isolates!)



Equivalent genomes of two species,
but differing copy numbers



Accurate quantification is key to differentiate between members of mycobiome which may be transient due to inhalation and those which are infecting

A novel amplicon target, TEF


- Single copy gene
- More consistently sized amplicon
- Can distinguish between closely related fungal pathogens
- Small amplicon size means can use Illumina benchtop sequencer: iSeq100



Mock fungal communities for assay validation

- Mock fungal communities – mixes of genomic DNA from 5 species
- Dilute genomic DNA to haploid genome equivalents & combine
- Each mock has a single species at high abundance and all remaining species are at low abundance (2%)


An Aspergillus fumigatus 'high' mix




Sequencing library preparation



Amplicon PCR - Mock communities used as PCR template




Barcoding allows us to process multiple samples




Index PCR adds sequencing adaptors




Libraries are ready to sequence




Mock community analysis identifies ITS1 under-representation of filamentous fungi




Mock community analysis identifies ITS1 under-representation of filamentous fungi



Issue translates into poor ITS1 species identification rates



Determining assay limit of detection



- Cystic fibrosis sputum sample spiked with *A. fumigatus* DNA
- 2, 10 or 25 haploid genome equivalents per PCR reaction


Species

- *Aspergillus fumigatus*
- *Malassezia restricta*

Assay validation with clinical samples


- Patient samples positive by *Aspergillus* qPCR

A. fumigatus read counts



Assay can detect *A. fumigatus*

Relative abundance of all Fungi



..and also other clinically relevant species


Searching for fungi in covid patient samples

- Covid-associated pulmonary aspergillosis (CAPA) reported in literature – varying incidence
- 32 covid patient samples
- 4 extraction negative controls
- 6 no template controls

Output: 3 samples with significant fungal counts

- 1) *C. albicans*
- 2) *A. fumigatus*
- 3) *C. parapsilosis*

Potential CAPA incidence of ~3%




Summary


- Mycobiome sequencing is a promising tool to provide fungal diagnostics with broad range and speciation.
- The established ITS1 target can significantly under-represent filamentous fungi in mixed communities, leading to poor ID rates
- Novel target can identify filamentous fungi, even when present at 2%, and can ID as few as 2 copies of *A. fumigatus* in a sputum sample.
- Assay validation with clinical samples is ongoing – preliminary data shows it can identify *A. fumigatus* but also reveal additional fungal pathogens - eg. *Scedosporium* – which may inform drug treatments

Looking to the future

- Combined fungal and bacterial pathogen identification?
- Combined pathogen ID & resistance screening?
- Drug discovery?



DOI: 10.1128/MMBR.00044-18



DOI: 10.1126/science.aap7999

Acknowledgements



Michael Bromley
Paul Bowyer
Sara Gago



Malcolm Richardson
Riina Richardson
David Denning
Lily Novak-Frazer



Thanks for listening!

